Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06233942 · ClinicalTrials.gov registry record · Phase 1
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by BeOne Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 308
- Enrollment target
- 20
- Study locations
NCT06233942 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 308 participants, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (61% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT06233942, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by BeOne Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 308 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a first-in-human, dose finding and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C9074 alone and in combination with other anticancer therapies in patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Tislelizumab
- DRUG BG-C9074
Study Locations (20)
Other
- Hospital Sirio Libanes Brasilia - Brasília
- Liga Norte Riograndene Contra O Cancer - Natal
- Hospital Sao Lucas Da Pucrs - Porto Alegre
- Instituto Nacional de Cancer Hospital Do Cancer Ii - Rio de Janerio
- Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto - São José do Rio Preto
- Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira - São Paulo
- Clinica de Pesquisa E Centro de Estudos Em Oncologia Ginecologica E Mamaria - São Paulo
New South Wales
- Blacktown Cancer and Haematology Centre - Blacktown
- Macquarie University - North Ryde
- Cancer Care Wollongong - Wollongong
Victoria
- Monash Health - Clayton
- Cabrini Hospital Malvern - Malvern East
- Peter Maccallum Cancer Centre - Melbourne
California
- Usc Norris Comprehensive Cancer Center (Nccc) - Los Angeles
Colorado
- University of Colorado Cancer Center - Aurora
Florida
- Florida Cancer Specialist Research Institute Lake Nona - Orlando
Maryland
- Sidney Kimmel Comprehensive Cancer At Johns Hopkins - Baltimore
Ohio
- James Cancer Hospital and Solove Research Institute - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 308 participants |
| Start Date | 2024-04-12 |
| Est. Completion | 2028-05-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06233942
The ClinicalTrials.gov registry entry for NCT06233942 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 308 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (61% higher). The listed sponsor is BeOne Medicines, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT06233942 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, New South Wales, Victoria.
Frequently Asked Questions
What is clinical trial NCT06233942 about?
NCT06233942 is a clinical study titled "Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors". This is a first-in-human, dose finding and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C9074 alone and in combination with other anticancer therapies in patients with advanced solid tumors.
What is the current status of trial NCT06233942?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 308 participants. The study started on 2024-04-12. Estimated completion is 2028-05-15.
What conditions does trial NCT06233942 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT06233942?
The interventions under investigation include: Bevacizumab (DRUG), Tislelizumab (DRUG), BG-C9074 (DRUG).
Who is sponsoring clinical trial NCT06233942?
This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06233942 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Maryland, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.